US 12,433,875 B2
(R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or its salt also in polymorphic form a for use in the prevention of heterotopic ossification
Lucio Claudio Rovati, Monza (IT); Gianfranco Caselli, Milan (IT); and Tiziana Piepoli, Milan (IT)
Assigned to Rottapharm Biotech S.R.L., Monza (IT)
Appl. No. 17/780,611
Filed by ROTTAPHARM BIOTECH S.R.L., Monza (IT)
PCT Filed Nov. 27, 2020, PCT No. PCT/EP2020/083719
§ 371(c)(1), (2) Date May 27, 2022,
PCT Pub. No. WO2021/105419, PCT Pub. Date Jun. 3, 2021.
Claims priority of application No. 19212463 (EP), filed on Nov. 29, 2019.
Prior Publication US 2023/0028519 A1, Jan. 26, 2023
Int. Cl. A61K 31/438 (2006.01); A61P 19/08 (2006.01)
CPC A61K 31/438 (2013.01) [A61P 19/08 (2018.01)] 14 Claims
 
1. A method for the prevention of heterotopic ossification in a subject affected by a disease selected from the group consisting of Myositis Ossificans, Post Surgical Heterotopic Ossification, Post-Injury Ossification, Osteosarcoma, at least one Spondyloarthropathy, at least one Seronegative arthropathy, Diffuse idiopathic skeletal hyperostosis, Para-articular Ossification, at least one Crystal-Induced Arthropathy, Osteoarthritis driven by degenerative processes, Hyperparathyroidism, Drug-Induced Ossification, and Ochronosis, Diffuse Idiopathic Skeletal Hyperstosis, Fibrodysplasia ossificans progressive, Synovial Endochromatosis and Progressive Osseous Heteroplasia, wherein said method comprises the step of administering to the subject a compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl)benzoic acid or a pharmaceutically acceptable salt thereof.